Evaluation of the nasal adjuvant activity of angiotensin peptide Ang-(1-7)

血管紧张素肽Ang-(1-7)的鼻佐剂活性评价

• 批准号: 8431730
• 负责人: Herman F Staats
• 金额: $ 23.49万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-03-01 至 2015-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8431730
• 关键词: Address; Adjuvant; Adverse effects; Angiotensins; Anthrax disease; Antigens; Attenuated Vaccines; Binding; Biological Assay; CD8B1 gene; Cholera Toxin; Data; Developing Countries; Development; Emergency Situation; Environment; Epitopes; Evaluation; Foundations; General Population; Gold; HIV-1; Health Personnel; Human; IgE; Immune response; Immune system; Immunity; Immunization; Immunoglobulin A; Immunoglobulin G; Infectious Agent; Inflammatory; Injection of therapeutic agent; Learning; Life; Lymphoid Tissue; Methods; Monitor; Nasal cavity; Needles; Nose; Peptides; Population; Proteins; Public Health; Publishing; Recombinants; Route; Safety; Serum; Signal Transduction; Smallpox Vaccine; Staging; Subunit Vaccines; Testing; Toxic effect; Training; Vaccination; Vaccine Adjuvant; Vaccine Antigen; Vaccine Design; Vaccines; Virus; Work; angiotensin I (1-7); anthrax protective factor; cell mediated immune response; enzyme linked immunospot assay; experience; immunogenicity; mouse model; mucosal vaccine; novel; preclinical study; receptor; response; tool; vaccine delivery; vaccine development; vaccine efficacy

DESCRIPTION (provided by applicant): Studies proposed in this application will evaluate the adjuvant activity of a natural peptide product when delivered using the needle-free method of intranasal mucosal immunization. We will build upon previous published studies from our group and utilize anthrax recombinant protective antigen (rPA) and a peptide immunogen to evaluate the natural peptide angiotensin-(1-7) (Ang-(1-7)) for its ability to provide nasal adjuvant activity for the induction of serum and mucosal antigen-specific humoral and cell- mediate immune responses to include serum IgG, mucosal IgA as well as systemic and mucosal epitope-specific CD8 responses. We will also initiate studies to better define the mechanism of action of this natural peptide adjuvant. Our specific aims are listed below and will utilize a mouse model of nasal immunization to perform early-stage preclinical studies to determine the safety and efficacy of Ang-(1-7) as a nasal vaccine adjuvant when compared to the gold-standard mucosal adjuvant cholera toxin (cholera toxin is not suitable for use in humans due to numerous toxicities). Information learned by the completion of the studies proposed in this application will provide a foundation for the development of a novel, natural peptide for use as an adjuvant for needle-free mucosal vaccines. Our specific aims are: Aim 1. Evaluate the nasal adjuvant activity of Ang-(1-7) when nasally delivered with protein or peptide immunogens. Studies performed in this aim will evaluate the adjuvant activity of Ang-(1-7) when nasally delivered with a protein antigen (anthrax protective antigen) or a peptide immunogen (C4-V3 HIV-1 peptide). When using the protein antigen, we will monitor vaccine-induced antigen-specific serum IgG, IgA and IgE responses as well as mucosal IgA. When using the peptide antigen, we will monitor the induction of epitope-specific CD8 responses using IFN3 ELISPOT and tetramer assays. The adjuvant activity of Ang-(1-7) will be compared to control adjuvants cholera toxin and CpG. Aim 2. Perform studies to evaluate the mechanism of action of Ang-(1-7) and its safety when used as a nasal vaccine adjuvant. Ang-(1-7) is known to signal via the MAS receptor. Studies performed in this aim will utilize the MAS antagonist A-779 to determine if the MAS receptor is required for the adjuvant activity of Ang-(1-7) and to determine if the use of Ang-(1-7) influences the cellular composition of the nasal cavity lymphoid tissue after nasal vaccination. Additional studies will evaluate the safety of Ang-(1-7) when used as a nasal vaccine adjuvant.

描述（由申请人提供）：本申请中提出的研究将评估天然肽产品在使用鼻内粘膜免疫无针方法时的佐剂活性。我们将在本小组先前发表的研究的基础上，利用炭疽重组保护性抗原（rPA）和一种肽免疫原来评估天然肽血管紧张素-(1-7)（Ang-(1-7)）为诱导血清和粘膜抗原特异性体液和细胞介导的免疫反应提供鼻佐剂活性的能力，包括血清IgG、粘膜IgA以及全身和粘膜表位特异性CD8反应。我们还将开展研究，以更好地确定这种天然肽佐剂的作用机制。我们的具体目标如下，并将利用小鼠鼻腔免疫模型进行早期临床前研究，以确定Ang-(1-7)作为鼻疫苗佐剂与金标准粘膜佐剂霍乱毒素（霍乱毒素因其众多毒性而不适合用于人类）相比的安全性和有效性。通过完成本申请中提出的研究获得的信息将为开发一种新型天然肽作为无针粘膜疫苗的佐剂提供基础。我们的具体目标是：目标1。评估Ang-(1-7)与蛋白质或肽免疫原一起经鼻给药时的鼻佐剂活性。在此目的下进行的研究将评估Ang-(1-7)在与蛋白质抗原（炭疽保护性抗原）或肽免疫原（C4-V3 HIV-1肽）一起鼻腔递送时的佐剂活性。当使用蛋白抗原时，我们将监测疫苗诱导的抗原特异性血清IgG， IgA和IgE反应以及粘膜IgA。当使用肽抗原时，我们将使用IFN3 ELISPOT和四聚体检测来监测表位特异性CD8反应的诱导。Ang-(1-7)的佐剂活性将与控制佐剂霍乱毒素和CpG进行比较。目标2。开展研究，评估Ang-(1-7)的作用机制及其作为鼻用疫苗佐剂的安全性。已知Ang-(1-7)通过MAS受体发出信号。为此目的进行的研究将利用MAS拮抗剂A-779来确定MAS受体是否需要Ang-(1-7)的佐剂活性，并确定Ang-(1-7)的使用是否影响鼻腔免疫接种后鼻腔淋巴组织的细胞组成。进一步的研究将评估Ang-(1-7)作为鼻用疫苗佐剂的安全性。